Anti-mgp75-mIgG2a InvivoFit™
-
Cat.code:
mgp75-mab10-1
- Documents
ABOUT
Recombinant mouse gp75 antibody for in vivo use
Anti-mgp75-mIgG2a InvivoFit™ is a recombinant mouse IgG2a monoclonal antibody (mAb) based on the previously described clone TA99. This clone reacts against the human and mouse tumor-associated antigen antigen glycoprotein 75 (gp75) [1]. The sequence of Anti-mgp75-mIgG2a InvivoFit™ is 100% murine (constant and variable regions), thus ensuring minimal immunogenicity upon repeated injections into mice. This mAb efficiently induces protective immunity against B16F10 melanoma, either subcutaneous or metastatic [2]. Of note, the mIgG2a isotype was shown to be the most potent at inducing antibody-dependent cellular cytotoxicity compared to mIgG1, mIgG2b, and mIgG3 [3]. As opposed to the original hybridoma-based production which contains a mixed population of anti-gp75 antibodies featuring correct or aberrant light chains [4], InvivoGen produces the recombinant anti-mgp75-mIgG2a mAb using Chinese hamster ovary (CHO) cells.
Anti-mgp75-mIgG2a is purely monoclonal and is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies.
Key features of Anti-mgp75-mIgG2a InvivoFit™:
- Sequence is 100% murine
- Free from non-relevant mAbs found in hybridoma-based productions
- Filter-sterilized (0.2 µm), endotoxin level < 1 EU/mg
- Suitable for parenteral delivery in mice (azide-free)
- Low aggregation < 5%
- Produced in animal-free facilities and defined media
Anti-mgp75-mIgG2a InvivoFit™ is purified by affinity chromatography with protein A. Its binding to mouse gp-75 is validated using ELISA.
References:
1. Thomson T.M. et al., 1985. Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. J Invest Dermatol. 85(2):169-74.
2. Hara I. et al., 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 182(5):1609-14.
3. Nimmerjahn F. & Ravetch J.V., 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310(5753):1510-2.
4. Boross P. et al., 2014. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice. Immunol Lett. 160(2):151-7.
All products are for research use only, and not for human or veterinary use.
InvivoFit™
InvivoFit™ is a high-quality standard specifically adapted for in vivo studies. InvivoFit™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and a TLR2 and TLR4 reporter assay.
SPECIFICATIONS
Specifications
gp75, TYRP1, MEL-5
Mouse
in vivo studies, ELISA
Sodium chloride, sodium phosphate buffer, saccharose
0.2 µm filtration
ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-mgp75-mIgG2a InvivoFit™
-
Cat code:mgp75-mab10-1
-
Quantity:1 mg
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Glycoprotein 75 (gp75) is a tumor-associated antigen specifically located within the membrane of melanosomes; the organelles producing melanin in melanocytes. This 75-kDa polypeptide is the mature form of tyrosinase-related protein 1 (TYRP1; also known as MEL-5).
This enzyme is the most abundant glycoprotein synthesized by pigmented melanocytes and melanomas. It is involved in melanin synthesis as well as the proliferation and cell death of melanocytes. Importantly, gp75 is a target of choice for antibody-based immunotherapy against primary and metastatic melanoma.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?